Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

439
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
439
Clinical Trials01:16

Clinical Trials

10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

316
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
316
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Cardiac Catheterization II: Right Heart Catheterization01:21

Cardiac Catheterization II: Right Heart Catheterization

1.3K
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
1.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

545
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
545

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vertical Displacement Index and Early Treatment-Related Physiological Improvement in Acute Respiratory Failure: An Exploratory Ultrasound-Based Study.

Advances in respiratory medicine·2026
Same author

Rapid authentication and adulteration detection of Sherry wine vinegar using ATR-FTIR spectroscopy coupled with chemometric and ANN approaches.

Food chemistry·2026
Same author

Revisiting parathyroid carcinoma through the lens of the 2022 WHO classification.

Hormones (Athens, Greece)·2026
Same author

In silico and in vitro insights into the wound-healing potential of syringic acid: protective and regenerative effects on human fibroblasts.

BMC pharmacology & toxicology·2026
Same author

Development of Styryl-Modified 3,4-Dihydropyrimidin-2(1H)-ones as Potential Antitumor Agents.

ChemMedChem·2026
Same author

Impact of centre volume on adrenalectomy outcomes: European multicentre study based on EUROCRINE® registry.

BJS open·2026

Related Experiment Video

Updated: Feb 22, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

981

[PIONEER AF-PCI trial].

Murat Özdemir1

  • 1Department of Cardiology, Gazi University Faculty of Medicine, Ankara, Turkey. hmurozdemir@gmail.com.

Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
|September 27, 2017
PubMed
Summary
This summary is machine-generated.

For atrial fibrillation patients needing coronary stenting, triple therapy with oral anticoagulation and dual antiplatelet therapy increases bleeding risk. The PIONEER AF-PCI trial provides crucial data on managing this complex patient group.

More Related Videos

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K

Related Experiment Videos

Last Updated: Feb 22, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

981
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Managing oral anticoagulation (OAC) in atrial fibrillation (AF) patients undergoing coronary stenting is challenging.
  • Dual antiplatelet therapy (DAPT) is standard post-stenting, but adding OAC (triple therapy) significantly elevates bleeding risk.
  • Limited prospective data existed for optimal triple therapy duration.

Purpose of the Study:

  • To summarize the results of the PIONEER AF-PCI trial.
  • To provide evidence-based guidance on managing OAC and DAPT in AF patients post-coronary stenting.

Main Methods:

  • The PIONEER AF-PCI trial was a prospective, randomized study.
  • Investigated different strategies for oral anticoagulation and dual antiplatelet therapy in AF patients post-PCI.

Main Results:

  • Triple therapy, while effective for preventing thrombotic events, is associated with a high incidence of bleeding.
  • Shorter durations of triple therapy followed by dual therapy showed reduced bleeding without compromising efficacy.

Conclusions:

  • The PIONEER AF-PCI trial offers critical insights into balancing antithrombotic efficacy and safety.
  • Recommendations for limited use of triple therapy in AF patients undergoing coronary stenting are supported by these findings.